Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS) PR Newswire FINTEPLA ® has demonstrated efficacy in the most difficult-to-treat seizure types, 1 ,2 including drop se...
New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting PR Newswire Eleven abstracts highlight new data on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis...
UCB (OTCPK:UCBJF) has completed its acquisition of Zogenix (ZGNX), a deal valued at up to $1.9B. The Belgian company acquired Zogenix (ZGNX) for $26 per share plus a milestone-based contingent value right for a potential cash payment of $2 per share. As a result, Zogenix (ZGNX) was delis...
The following slide deck was published by UCB SA in conjunction with their 2021 Q4 earnings call. For further details see: UCB SA 2021 Q4 - Results - Earnings Call Presentation
UCB SA (UCBJF) Q4 2021 Earnings Conference Call February 24, 2022, 8:00 AM ET Company Participants Jean-Christophe Tellier – Chief Executive Officer Sandrine Dufour – Chief Financial Officer Iris Löw-Friedrich – Chief Medical Officer Antje Witte – Vice Preside...
UCB SA press release (OTCPK:UCBJF): FY Non-GAAP EPS of €6.49. Revenue of €5.78B (+8.0% Y/Y). For further details see: UCB SA Non-GAAP EPS of €6.49, revenue of €5.78B
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results - Positive topline results show the Phase 3 RAISE (NCT04115293) zilucoplan trial met primary and all key secondary endpoints in adults with generalized myasthenia gravis - The results show...
Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study - The BE COMPLETE study evaluated bimekizumab in adults with active psoriatic arthritis who were inadequate responders or intolerant to anti-TNF treatment - BE COMPLETE is the second positi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Zogenix (NASDAQ: ZGNX ) stock is skyrocketing on Wednesday following news that UCB (OTCMKTS: UCBJY ) intends to acquire the company in a $1.9 billion deal. Source: Shutterstock.com The deal between the t...
UCB to acquire Zogenix - Transaction broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy, complementing existing medicines and expanding clinical development pipeline of epilepsy and rare dise...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated ...